Product liability cases are generally pretty straight forward – a company manufactures/distributes a product that has caused injury. If that company didn’t make full disclosure of the risks to the patients and/or healthcare workers and people are harmed from those risks, then it is just to hold them accountable. Generally, doctors are not part of the product liability cases.
But, this article highlights the fault in generalizing product liability cases like that.
Since early 2014, it has been public knowledge (at least in medical communities) that using a power morcellator during a hysterectomy shreds tissue into tiny particles so that it can be easily sucked through a tiny opening during a minimally invasive operation. If the morcellator is being used on fibroids that are cancerous, then the cancerous mass will be broken into tiny particles that are quickly spread through the abdomen and this procedure has been linked to a very rare and aggressive cancer called leiomyosarcoma.
Despite the fact that a Boston anesthesiologist and her husband became vocal activists in December 2013 (upon her diagnosis with the same cancer), the FDA issued a safety communication to health professionals in April 2014, and public hearings were held in July 2014, there are still doctors that were performing hysterectomies using power morcellator in October 2014 and later. Those doctors should not be immune from being held accountable for the risks they took with their patients.
This article is the story of one woman who is currently fighting for her life in a New York hospital as a result of a hysterectomy in which her doctors used a power morcellator.
Background information prepared by the FDA for the panel members of the advisory committee that recommended the FDA approval of the first female libido drug, Addyi flibanserin.
New anticoagulant drugs are looking to capture the lucrative market for anticoagulants that has been dominated by warfarin, a drug approved by the FDA in 1954 that requires medical monitoring. More than $3.5 billion was spent on these new drugs in 2014 with a cost of more than $1 billion to taxpayers. But, without an antidote to stop bleeding events, many are questioning the risk/reward of switching to these new drugs. Pradaxa, Eliquis and Xarelto lawyers continue to talk to individuals harmed by these drugs with lawsuits moving forward for many of these individuals.